PDLIM7 and prostate carcinoma: To determine whether these compounds were able to induce LMP in aggressive and drug resistant prostate cancer cell lines, PC3 cells were treated with increasing doses of these lysosomotropic agents for 4 h and analyzed by flow cytometry using the Lysotracker fluorescent dye.